Press Releases
Sep 29, 2020
Summary ToggleIntellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment
In Vivo gene knockout and insertion data to be presented at OTS Annual Meeting highlight modularity of Intellia’s platform and potential for variety of single-course therapies, with company’s first systemic treatment (NTLA-2001) expected to enter the clinic by year-end
Sep 28, 2020
Summary ToggleIntellia Therapeutics to Present at Chardan’s Virtual 4th Annual Genetic Medicines Conference
CAMBRIDGE, Mass. , Sept. 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at Chardan’s Virtual 4 th Annual Genetic Medicines
Sep 2, 2020
Summary ToggleIntellia Therapeutics to Present at Baird’s 2020 Virtual Global Healthcare Conference
CAMBRIDGE, Mass. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at Baird’s 2020 Virtual Global Healthcare Conference on
Aug 6, 2020
Summary ToggleIntellia Therapeutics Announces Second Quarter 2020 Financial Results
Submitted first regulatory application to the U.K.’s MHRA to initiate a Phase 1 study of NTLA-2001 for the treatment of transthyretin amyloidosis; on track to dose first patient by year-end Expanded Regeneron collaboration, receiving $100 million through upfront cash and equity investment and
Aug 3, 2020
Summary ToggleIntellia Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
CAMBRIDGE, Mass. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Jul 30, 2020
Summary ToggleIntellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2020 Earnings and Company Updates
CAMBRIDGE, Mass. , July 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its second quarter 2020 financial results and operational
Jun 5, 2020
Summary ToggleIntellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass. , June 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , today announced the closing of an underwritten public offering of
Jun 2, 2020
Summary ToggleIntellia Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. , June 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today the pricing of an underwritten public offering of
Jun 1, 2020
Summary ToggleIntellia Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today that it has commenced an underwritten public
Jun 1, 2020
Summary ToggleRegeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
Regeneron and Intellia to co-develop potential hemophilia A and B treatments using their jointly-owned targeted transgene insertion capabilities Regeneron gains rights to develop products for additional in vivo targets and new rights for ex vivo product development Intellia receives $100 million
